Immunocore reports first quarter financial results and provides a business update
Immunocore reported Q1 2026 net product sales of $106.7 million, up 13.6% year-over-year, driven by volume growth in the U.S. and Europe. Net income more than doubled to $13.0 million, or $0.25 per diluted share, compared to the prior year. Landmark five-year overall survival data presented at AACR showed KIMMTRAK doubled the likelihood of survival at five years compared to control, with a median OS of 21.6 months.
Key figures
- Eps
- 0.25
- Revenue
- 106700000
- Revenue Yoy
- 13.6%
- Net income
- 13000000
- Rd expenses
- 61100000
- Sga expenses
- 37900000
- Cash position
- 845000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.